Vasoactive intestinal peptide; VPAC1/VPAC2 receptor agonist
PRODUCT PROFILE
VIP
Price range: £29.99 through £38.99
VIP is vasoactive intestinal peptide; vpac1/vpac2 receptor agonist. Researchers examine it in relation to vasodilation, airway smooth muscle, secretion and immune regulation.
Why it is distinct
A receptor-defined pleiotropic neuropeptide with direct vasodilatory and bronchodilatory effects.
- Evidence stageClinical research
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
VIP is vasoactive intestinal peptide; vpac1/vpac2 receptor agonist. Researchers examine it in relation to vasodilation, airway smooth muscle, secretion and immune regulation.
Research focus+
Researchers study these wide-ranging effects in specialist clinical settings. Its broad actions also mean safety and context matter.
How the mechanism differs+
Raises intracellular cAMP through VPAC receptors across vascular, pulmonary, gastrointestinal and immune tissues.
Evidence and limitations+
Extensive human physiology and clinical investigation exist, but outcomes depend strongly on disease, formulation and delivery.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study these wide-ranging effects in specialist clinical settings. Its broad actions also mean safety and context matter.
Raises intracellular cAMP through VPAC receptors across vascular, pulmonary, gastrointestinal and immune tissues.
A receptor-defined pleiotropic neuropeptide with direct vasodilatory and bronchodilatory effects.
Extensive human physiology and clinical investigation exist, but outcomes depend strongly on disease, formulation and delivery.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Bronchogen
£46.0020 mgBatch file pendingAirway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.
UnavailableAsk about availability -
Early human evidence
LL-37
£59.005 mgBatch file pendingDirect antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
UnavailableAsk about availability -
Established
Thymosin Alpha-1
£69.0010 mgBatch file pendingAn immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
UnavailableAsk about availability -
Experimental
Vilon
£46.0020 mgBatch file pendingA minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
UnavailableAsk about availability